• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Newsletters » CenterWatch Weekly

CenterWatch Weekly Sign Up Now

May 29, 2023

View Archived Issues

Download Current Issue:

  • CenterWatch Weekly, May 29, 2023
MAGI East 2023

MAGI East 2023: Innovation Adoption Takes Too Long, Getz Says

The clinical research industry is falling behind the innovation curve, says Ken Getz, executive director of the Tufts Center for the Study of Drug Development (CSDD), taking years — and sometimes decades — to evaluate, adopt and fully implement new technologies and methods. Read More
WCG Innovation Challenge

UNC’s Study Startup Mapping Tool Wins WCG Innovation Challenge

The University of North Carolina at Chapel Hill (UNC) School of Medicine’s innovative web-based solution to managing their trials’ startup processes was crowned the winner of this year’s Innovation Challenge at the 2023 MAGI East Clinical Research Conference in Philadelphia. Read More

Industry Briefs

ICH Advances Revised GCP Guideline, Requests Public Comment

The International Council on Harmonisation (ICH) has released the first two parts of a long-awaited third revision to ICH E6 – Good Clinical Practice and invited public comment on the draft that would replace and expand on the current GCP guideline, ICH E6(R2). Read More

Many Pivotal Cancer Trials Change Endpoints Mid-Study, But Few Report It, Study Says

One in five active phase 3 cancer trials changes its primary endpoints during the study but fewer than one-third of them report the modifications in publications, a new study published in JAMA Network Open found, adding another facet to industry concerns about trial transparency. Read More

Overheard at MAGI East 2023

The 2023 WCG MAGI East Clinical Research Conference held in Philadelphia last week brought together representatives of sites, sponsors, CROs and vendors to discuss key issues facing clinical trials. Here are just a few thoughts expressed by attendees and speakers at the conference. Read More

FDA Posts Trio of Clinical Research-Related Guidances

The FDA published three guidance documents for sponsors last week, providing advice on statistical analysis, endpoint selection and electronic data submission. Read More

Drug & Device Pipeline News

Twenty-seven drugs and devices were approved or entered a new trial phase last week. Read More

Research Center Profiles

Research Center Profiles are free to use and provide comprehensive listings of hundreds of institutional and independent sites. Read More

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing